Medigen Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
Medigen Biotechnology has a total shareholder equity of NT$5.0B and total debt of NT$2.6B, which brings its debt-to-equity ratio to 51.6%. Its total assets and total liabilities are NT$8.5B and NT$3.5B respectively.
Key information
51.6%
Debt to equity ratio
NT$2.58b
Debt
| Interest coverage ratio | n/a |
| Cash | NT$4.59b |
| Equity | NT$5.00b |
| Total liabilities | NT$3.53b |
| Total assets | NT$8.53b |
Financial Position Analysis
Short Term Liabilities: 3176's short term assets (NT$5.7B) exceed its short term liabilities (NT$2.8B).
Long Term Liabilities: 3176's short term assets (NT$5.7B) exceed its long term liabilities (NT$750.2M).
Debt to Equity History and Analysis
Debt Level: 3176 has more cash than its total debt.
Reducing Debt: 3176's debt to equity ratio has increased from 46.2% to 51.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3176 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 3176 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 0.3% each year